Search research articles
Contact Us
Filters
Showing results (11-20 of 205) with videos related to
Page
of 21
Sort By:
Therapeutic Advances in Medical Oncology
|
July 27, 2011
Targeted therapy in renal cancer
Tanya B Dorff, Amir Goldkorn, David I Quinn
Radiology
|
January 28, 2015
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases
Hossein Jadvar, Susan G Groshen, David I Quinn
Expert Review of Clinical Pharmacology
|
December 7, 2013
Novel tyrosine kinase inhibitors for renal cell carcinoma
Tanya B Dorff, Sumanta K Pal, David I Quinn
The Lancet. Oncology
|
December 3, 2014
Chromoplexy and hypoxic microenvironment drives prostate cancer
Leslie K Ballas, Brian R Hu, David I Quinn
Clinical Nuclear Medicine
|
September 6, 2011
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer
Bhushan Desai, Wafaa Elatre, David I Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2005
Molecular markers of prostate cancer outcome
David I Quinn, Susan M Henshall, Robert L Sutherland
Clinical Advances in Hematology & Oncology : H&O
|
March 13, 2012
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer
Andrew J Armstrong, Anna C Ferrari, David I Quinn
Oncology (Williston Park, N.Y.)
|
August 20, 2014
Salvage chemotherapy for refractory germ cell tumors
Tanya B Dorff, James S Hu, David I Quinn
Oncotargets and Therapy
|
October 8, 2016
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
Steven S Yu, David I Quinn, Tanya B Dorff
The Urologic Clinics of North America
|
May 3, 2005
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy
Ana M Aparicio, Anthony B Elkhouiery, David I Quinn
Page
of 21
Search research articles
Search
Showing results (11-20 of 205) with videos related to
Sort By:
Page
of 21
Therapeutic Advances in Medical Oncology
|
July 27, 2011
Targeted therapy in renal cancer
Tanya B Dorff, Amir Goldkorn, David I Quinn
Radiology
|
January 28, 2015
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases
Hossein Jadvar, Susan G Groshen, David I Quinn
Expert Review of Clinical Pharmacology
|
December 7, 2013
Novel tyrosine kinase inhibitors for renal cell carcinoma
Tanya B Dorff, Sumanta K Pal, David I Quinn
The Lancet. Oncology
|
December 3, 2014
Chromoplexy and hypoxic microenvironment drives prostate cancer
Leslie K Ballas, Brian R Hu, David I Quinn
Clinical Nuclear Medicine
|
September 6, 2011
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer
Bhushan Desai, Wafaa Elatre, David I Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2005
Molecular markers of prostate cancer outcome
David I Quinn, Susan M Henshall, Robert L Sutherland
Clinical Advances in Hematology & Oncology : H&O
|
March 13, 2012
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer
Andrew J Armstrong, Anna C Ferrari, David I Quinn
Oncology (Williston Park, N.Y.)
|
August 20, 2014
Salvage chemotherapy for refractory germ cell tumors
Tanya B Dorff, James S Hu, David I Quinn
Oncotargets and Therapy
|
October 8, 2016
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
Steven S Yu, David I Quinn, Tanya B Dorff
The Urologic Clinics of North America
|
May 3, 2005
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy
Ana M Aparicio, Anthony B Elkhouiery, David I Quinn
Page
of 21